Ignyta Announces Initiation Of STARTRK-1 Global Phase I/II Clinical Trial Of RXDX-101
July 21, 2014 at 07:00 AM EDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced the multicenter initiation of the ...